• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基因与相关癌症：来自流行病学队列研究的荟萃分析。

Genes and Related Cancers: A Meta-Analysis from Epidemiological Cohort Studies.

机构信息

Department of Oncology, Tainan Hospital, Ministry of Health and Welfare, Executive Yuan, Tainan 700, Taiwan.

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, Tainan 700, Taiwan.

出版信息

Medicina (Kaunas). 2021 Aug 30;57(9):905. doi: 10.3390/medicina57090905.

DOI:10.3390/medicina57090905
PMID:34577828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8464901/
Abstract

and are genes located in different chromosomes that are disproportionately associated with hereditary breast and ovarian cancer syndrome. Their association with other cancers remains to be explored. We systematically reviewed cohort studies to explore the association of and with various cancers except lung cancer. We searched PubMed, Medline (EBSCOhost) and relevant articles published up to 10 May 2021. The odds ratio, standardised morbidity rate and cancer-specific standardised incidence ratio were pooled together as relative risk (RR) estimates. Twelve studies were included for analysis. mutation increased pancreatic and uterine cancers by around 3-5- and 1.5-fold, respectively. mutation did not increase brain cancer; colorectal cancer; prostate, bladder and kidney cancer; cervical cancer; or malignant melanoma. increased gastric cancer with RR = 2.15 (1.98-2.33). The meta-analysis results can provide clinicians and relevant families with information regarding increased specific cancer risk in and mutation carriers.

摘要

和 是位于不同染色体上的基因，与遗传性乳腺癌和卵巢癌综合征不成比例地相关。它们与其他癌症的关联仍有待探索。我们系统地综述了队列研究，以探讨 和 与除肺癌以外的各种癌症的关联。我们检索了 PubMed、Medline（EBSCOhost）和截至 2021 年 5 月 10 日发表的相关文章。将比值比、标准化发病比和癌症特异性标准化发病比合并为相对风险（RR）估计值。纳入了 12 项研究进行分析。 突变使胰腺癌和子宫癌的风险分别增加了约 3-5 倍和 1.5 倍。 突变不会增加脑癌、结直肠癌、前列腺癌、膀胱癌和肾癌、宫颈癌或恶性黑色素瘤的风险。 突变使胃癌的 RR 增加到 2.15（1.98-2.33）。荟萃分析结果可为临床医生和相关家庭提供有关 和 突变携带者特定癌症风险增加的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/4aa4b80e546d/medicina-57-00905-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/ee7a43571a71/medicina-57-00905-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/af0c286b82ab/medicina-57-00905-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/751c48bf4147/medicina-57-00905-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/cdb2ecf67085/medicina-57-00905-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/1bc6997b26e6/medicina-57-00905-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/775c572f66a3/medicina-57-00905-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/6cdfcb81509a/medicina-57-00905-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/300e1a6a3500/medicina-57-00905-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/5c2120b67241/medicina-57-00905-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/0e9165f00b5d/medicina-57-00905-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/4aa4b80e546d/medicina-57-00905-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/ee7a43571a71/medicina-57-00905-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/af0c286b82ab/medicina-57-00905-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/751c48bf4147/medicina-57-00905-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/cdb2ecf67085/medicina-57-00905-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/1bc6997b26e6/medicina-57-00905-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/775c572f66a3/medicina-57-00905-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/6cdfcb81509a/medicina-57-00905-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/300e1a6a3500/medicina-57-00905-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/5c2120b67241/medicina-57-00905-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/0e9165f00b5d/medicina-57-00905-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be34/8464901/4aa4b80e546d/medicina-57-00905-g011.jpg

相似文献

1
Genes and Related Cancers: A Meta-Analysis from Epidemiological Cohort Studies.基因与相关癌症：来自流行病学队列研究的荟萃分析。
Medicina (Kaunas). 2021 Aug 30;57(9):905. doi: 10.3390/medicina57090905.
2
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.对携带BRCA1或BRCA2基因突变的女性进行降低风险的双侧输卵管卵巢切除术。
Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2.
3
Selenium for preventing cancer.硒预防癌症。
Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD005195. doi: 10.1002/14651858.CD005195.pub4.
4
Prognostic factors for return to work in breast cancer survivors.乳腺癌幸存者恢复工作的预后因素。
Cochrane Database Syst Rev. 2025 May 7;5(5):CD015124. doi: 10.1002/14651858.CD015124.pub2.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database.利用日本遗传性乳腺癌和卵巢癌联盟（HBOC）以及日本遗传性乳腺癌和卵巢癌组织（JOHBOC）登记项目数据库，分析对乳腺癌女性应用BRCA基因检测的条件。
Breast Cancer. 2025 May 5. doi: 10.1007/s12282-025-01704-8.
7
A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?BRCA 胚系突变携带者的乳腺癌和卵巢癌中 BRCA 启动子甲基化频率的系统评价：相互排斥，还是不排斥？
Crit Rev Oncol Hematol. 2018 Jul;127:29-41. doi: 10.1016/j.critrevonc.2018.05.008. Epub 2018 May 14.
8
Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.BRCA1或BRCA2基因突变未患病携带者中筛查和预防性手术的应用情况。
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):1989-95.
9
Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer registry data.基于日本遗传性乳腺癌和卵巢癌登记数据组织，开发用于预测日本乳腺癌患者携带BRCA1/2致病变异的新型模型。
Breast Cancer Res Treat. 2025 Jan;209(1):177-188. doi: 10.1007/s10549-024-07485-6. Epub 2024 Oct 2.
10
Risk-reducing mastectomy for the prevention of primary breast cancer.预防性乳房切除术以预防原发性乳腺癌。
Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD002748. doi: 10.1002/14651858.CD002748.pub4.

引用本文的文献

1
Secondary Findings from Exome Sequencing of a Greek Cohort.希腊队列外显子组测序的次要发现
Curr Issues Mol Biol. 2025 Apr 11;47(4):272. doi: 10.3390/cimb47040272.
2
Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers.拓展遗传性乳腺癌卵巢癌综合征（HBOC）的基因组格局及突变携带者的癌症风险
Int J Mol Sci. 2025 Jun 20;26(13):5928. doi: 10.3390/ijms26135928.
3
Case Report: Influence of BRCA1 germline mutation on treatment-related morbidity of a non-seminomatous germ cell tumor patient.病例报告：BRCA1 种系突变对非精原细胞性生殖细胞肿瘤患者治疗相关发病率的影响。

本文引用的文献

1
Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis.遗传性 BRCA 基因突变携带者的子宫内膜癌：系统评价和荟萃分析。
J Minim Invasive Gynecol. 2021 May;28(5):947-956. doi: 10.1016/j.jmig.2020.11.023. Epub 2020 Nov 27.
2
Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis.BRCA突变与子宫内膜癌之间的关联：一项荟萃分析的系统评价
Arch Gynecol Obstet. 2021 Jun;303(6):1569-1579. doi: 10.1007/s00404-020-05887-7. Epub 2020 Nov 20.
3
and Gene Mutations and Lung Cancer Sisk: A Meta-Analysis.
Front Oncol. 2025 May 30;15:1579574. doi: 10.3389/fonc.2025.1579574. eCollection 2025.
4
Clinical Characteristics and Survival in Patients with Brain Metastases From Pancreatic Cancer: A Retrospective Observational Study.胰腺癌脑转移患者的临床特征与生存情况：一项回顾性观察研究
Cancer Control. 2025 Jan-Dec;32:10732748251347844. doi: 10.1177/10732748251347844. Epub 2025 Jun 4.
5
Occurrence of Malignancies Other than Breast and Ovarian Cancer in Female Carriers of a Germline Pathogenic Variant.携带生殖系致病变异的女性中除乳腺癌和卵巢癌以外的其他恶性肿瘤的发生情况
Cancers (Basel). 2025 May 17;17(10):1687. doi: 10.3390/cancers17101687.
6
Synchronous multiple primary cancers involving cervical cancer and follicular lymphoma: A case report.同步发生的涉及宫颈癌和滤泡性淋巴瘤的多原发性癌：一例报告。
Oncol Lett. 2025 Feb 13;29(4):183. doi: 10.3892/ol.2025.14930. eCollection 2025 Apr.
7
Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).前列腺癌骨转移：分子机制、靶向诊断与靶向治疗（综述）
Oncol Rep. 2025 Apr;53(4). doi: 10.3892/or.2025.8879. Epub 2025 Feb 21.
8
Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors.低剂量DNA甲基转移酶抑制剂增强PARP抑制剂在同源重组修复缺陷肿瘤中的作用。
Breast Cancer Res. 2025 Jan 16;27(1):8. doi: 10.1186/s13058-024-01954-y.
9
The Assessment of Knowledge About Cervical Cancer, HPV Vaccinations, and Screening Programs Among Women as an Element of Cervical Cancer Prevention in Poland.波兰女性对宫颈癌、人乳头瘤病毒疫苗接种及筛查项目的知识评估作为宫颈癌预防要素的研究
J Pers Med. 2024 Dec 4;14(12):1139. doi: 10.3390/jpm14121139.
10
Exploring the Complex Mechanisms of Isoflavones: From Cell Bioavailability, to Cell Dynamics and Breast Cancer.探索异黄酮的复杂机制：从细胞生物利用度到细胞动态变化与乳腺癌
Phytother Res. 2025 Feb;39(2):957-979. doi: 10.1002/ptr.8417. Epub 2024 Dec 20.
并基因突变与肺癌：荟萃分析。
Medicina (Kaunas). 2020 Apr 27;56(5):212. doi: 10.3390/medicina56050212.
4
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.BRCA1 和/或 BRCA2 基因突变携带者结直肠癌发病风险的系统评价和荟萃分析。
Br J Surg. 2020 Jul;107(8):951-959. doi: 10.1002/bjs.11603. Epub 2020 Apr 16.
5
The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.BRCA1 和 BRCA2 突变与前列腺癌风险、频率和死亡率的关联：一项荟萃分析。
Prostate. 2019 Jun;79(8):880-895. doi: 10.1002/pros.23795. Epub 2019 Mar 22.
6
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.BRCA1 和 BRCA2 基因突变与结直肠癌风险：系统评价和荟萃分析。
J Natl Cancer Inst. 2018 Nov 1;110(11):1178-1189. doi: 10.1093/jnci/djy148.
7
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.BRCA1 突变特异性对 53BP1 缺失诱导的同源重组和 PARP 抑制剂耐药的反应。
Cell Rep. 2018 Sep 25;24(13):3513-3527.e7. doi: 10.1016/j.celrep.2018.08.086.
8
BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.BRCA1和BRCA2基因检测——处理临床意义不确定变异的陷阱与建议
Ann Oncol. 2015 Oct;26(10):2057-65. doi: 10.1093/annonc/mdv278. Epub 2015 Jul 7.
9
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.除乳腺癌和卵巢癌外，与BRCA1和BRCA2基因突变相关的癌症。
Cancer. 2015 Jan 15;121(2):269-75. doi: 10.1002/cncr.29041. Epub 2014 Sep 15.
10
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.BRCA1和BRCA2突变携带者的靶向前列腺癌筛查：IMPACT研究首轮筛查结果
Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15.